The expenditure consequences of the drug cimetidine for the period 1977-1979 are
investigated. Using Medicaid data for the State of Michigan, it is found that expenditures
for the first year of treatment of duodenal ulcers are reduced between 26% and 70%. The
methodology employed can be applied to the assessment of other medical technologies.
Get full access to this article
View all access options for this article.
References
1.
Wylie, J.H., J. Alexander-Williams, T.L. Kennedy, C.G. Clark, P.R.F. Bell, R.M. Kirk, and C. MacKay (1981) "Effect of cimetidine on surgery for duodenal ulcer ." The Lancet, June 13: 1307-1308.
2.
Geweke, J. and B.A. Weisbrod (1982) "Clinical evaluation vs. economic evaluation: the case of a new drug" Medical Care20 (August): 821-830.
3.
———( 1981) "Some economic consequences of technological advance in medical care: the case of a new drug," in R. Helms (ed.) Drugs and Health: Economic Issues and Policy Objectives. Washington, DC: American Enterprise Institute for Public Policy Research.
4.
Ricardo-Campbell, R., M.M. Eisman, W.M. Wardell, and R. Crossley (1980) "Preliminary methodology for controlled cost-benefit study of drug impact: the effect of cimetidine on days of work lost in a short term trial in duodenal ulcer."The J. of Clinical Gastroenterology2: 37-41.
5.
State of Michigan, Department of Social Services (1979) Drug Class Code Listing, Data Element Description .
6.
U. S. Department of Commerce (1982) Statistical Abstract of the United States, 101.
7.
Weisbrod, B.A. (1981) "Benefit-cost analysis of a controlled experiment: treating the mentally ill." J. of Human ResourcesXVI (Fall): 523-548.
8.
Wylie, J.H., J. Alexander-Williams, K.L. Kennedy, C.G. Clark, P.R.F. Bell, R.M. Kirk, and C. MacKay (1981) "The effects of cimetidine on surgery for duodenal ulcers." The Lancet (June 13): 1307-1308.
